Explore the words cloud of the CELLUP project. It provides you a very rough idea of what is the project "CELLUP" about.
The following table provides information about the project.
RESOLUTION SPECTRA SYSTEMS
|Coordinator Country||France [FR]|
|Total cost||1˙969˙553 €|
|EC max contribution||1˙969˙553 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-08-01 to 2019-12-31|
Take a look of project's partnership.
|1||RESOLUTION SPECTRA SYSTEMS||FR (MEYLAN)||coordinator||1˙969˙553.00|
The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-line analytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and process control during the phases of process development, scale-up and manufacturing of vaccines and antibodies for human medicines based on eukaryote cells culture. This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients and metabolites during the mammalian cell culture inside the bioreactor. Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. The negative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phase and in terms of untapped production yield improvement. Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem by offering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor. Based on the needs expressed by several major industrial actors, the company has already developed a first product successfully evaluated and released end of 2016 under the name ProCellics. The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a new configuration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and a related software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success of this new methodology development is a cell culture activity carried internally by our company. The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years.
|Publication||Websites, patent fillings, videos etc.||2020-04-09 20:03:27|
|Webpage and blog||Websites, patent fillings, videos etc.||2019-09-02 11:57:24|
Take a look to the deliverables list in detail: detailed list of CELLUP deliverables.
|year||authors and title||journal||last update|
Laure P tillot, Fiona Pewny, Martin Wolf, C lia Sanchez, Fabrice Thomas, Johan Sarrazin, Katharina Fauland, Herman Katinger, Charlotte Javalet, Christophe Bonneville
Calibration transfer for bioprocess Raman monitoring using Kennard Stone Piecewise Direct Standardization and multivariate algorithms
published pages: , ISSN: , DOI: 10.22541/au.157989784.46222963
|Engineering report monthly||2020-03-05|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CELLUP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CELLUP" are provided by the European Opendata Portal: CORDIS opendata.
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccinationRead More